Colorectal cancer (CRC) has among the highest cancer mortality rate worldwide, with over 608,700 deaths per year. Annually, over one million new cases are diagnosed worldwide.
Current chemotherapy treatments available commonly use DNA damaging agents, which can have toxic side-effects. The APO-DECIDE project will use new predictive tools that will provide guidance in deciding whether or not a CRC patient will benefit from combination chemotherapy.
APO-DECIDE will develop and validate systems-based biomarkers for apoptosis susceptibility. This will identify patients who will respond to standard chemotherapy and also indicate if and how novel targeted therapeutics may be used at maximal benefit for patients.